ArticleBMC infectious diseases2016
Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Sexually transmitted and bloodborne infections testing among people who use substances: findings from the 2023 British Columbia Harm Reduction Client Survey.BMC infectious diseases · 2026Article
- Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).Implementation science communications · 2025Article
- Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement project.International journal for equity in health · 2025Article
- Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.Journal of virus eradication · 2024Article
- Epidemiology of Hepatitis C over 28 years of monitoring Canadian blood donors: Insight into a low-risk undiagnosed population.BMC public health · 2024Article
- Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers.International journal for equity in health · 2024Article
- Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada.Harm reduction journal · 2024Article
- Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.Lancet regional health. Americas · 2024Article
- Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.BMJ (Clinical research ed.) · 2023Article
- Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.International journal for equity in health · 2023Article
- National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Hepatitis C Co-infection in People Living With HIV-Epidemiologic Differences Between Men Who Have Sex With Men MSM and Non-MSM.Frontiers in public health · 2022Article
- Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort.Frontiers in oncology · 2022Article
- Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study.BMC women's health · 2021Article
- Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia.BMJ open diabetes research & care · 2021Article
- Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada.The International journal on drug policy · 2020Article
- Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy.Hepatology communications · 2019Article
- Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014.The American journal of medicine · 2018Article
- Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.World journal of gastroenterology · 2018Article
- Contextualizing Canada's hepatitis C virus epidemic.Canadian liver journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe characterized the twin epidemics of new and prevalent hepatitis C virus (HCV) infections in British Columbia, Canada to inform prevention, care and treatment programs.
methodsThe BC Hepatitis Testers Cohort (BC-HTC) includes individuals tested for HCV, HIV or reported as a case of HBV, HCV, HIV or active TB between 1990-2013 linked with data on their medical visits, hospitalizations, cancers, prescription drugs and mortality. Prevalent infection was defined as being anti-HCV positive at first test. Those with a negative test followed by a positive test were considered seroconverters or new infections.
resultsOf 1,132,855 individuals tested for HCV, 64,634 (5.8 %) were positive and an additional 3092 cases tested positive elsewhere for a total of 67,726. Of 55,781 HCV positive individuals alive at the end of 2013, 7064 were seroconverters while 48,717 had prevalent infection at diagnosis. The HCV positivity rate (11.2 %) was highest in birth cohort 1945-1964 which declined over time. New infections were more likely to be male, 15-34 years of age (born 1965-1984), HIV- or HBV-coinfected, socioeconomically disadvantaged, have problematic drug and alcohol use and a mental health illness. The profile was similar for individuals with prevalent infection, except for lower odds of HBV-coinfection, major mental health diagnoses and birth cohort >1975.
conclusionsThe HCV positivity rate is highest in birth cohort 1945-1964 which represents most prevalent infections. New infections occur in younger birth cohorts who are commonly coinfected with HIV and/or HBV, socioeconomically marginalized, and living with mental illness and addictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.